A Synthetic Human Cytomegalovirus Vaccine Platform

合成人巨细胞病毒疫苗平台

基本信息

  • 批准号:
    8687582
  • 负责人:
  • 金额:
    $ 27.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-07-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome a shortcoming of current technologies that require extensive in vitro passaging of HCMV which often results in selecting tissue-culture adapted viral variants that are unlikely to be infectious. As proof-of-principle we will recreate the wild-ype version of the clinical isolate Toledo which has been used previously in clinical trials. Preliminay data suggest that early passages of Toledo contain a mixture of genomes displaying both tissue-culture adapted and non-adapted genotypes. We will determine the genomic sequence of the genotypes present in this mixture and use a combination of oligonucleotide synthesis, polymerase chain reaction, in vitro and in vivo assembly to recreate in a step-wise fashion a HCMV genome that will most closely resemble the original, wild-type sequence used in humans. The resulting virus, as well as spread-deficient variants, will be reconstituted in vitro and its growth characteristics will be compared to that of laboratory-adapted strains and other clinical isolates in vitro and in vivo using humanized NOD/SCID/IL2Rg-nul mice. If successful, this project would a) greatly facilitate the generation of molecular clones of CMV directly from sequence information without prior tissue culture, b) result in the largest viral genome synthesized to date, c) revolutionize the genetic manipulation of herpesviral genomes as well as that of other large DNA viruses.
描述(由申请方提供):本项目的目标是基于基因组序列信息合成一种人巨细胞病毒(HCMV)毒株,该毒株已证明能够在血清阳性个体中建立持续感染。所得合成产物将形成减毒HCMV疫苗开发的基础。创新的合成生物学方法将克服当前技术的缺点,即需要大量的HCMV体外传代,这通常会导致选择不太可能具有感染性的组织培养适应性病毒变体。作为原理证明,我们将重新创建先前在临床试验中使用的临床分离株Toledo的野生型版本。实验数据表明,Toledo的早期传代包含显示组织培养适应和非适应基因型的基因组的混合物。我们将确定该混合物中存在的基因型的基因组序列,并使用寡核苷酸合成、聚合酶链反应、体外和体内组装的组合,以逐步的方式重新创建与人类中使用的原始野生型序列最相似的HCMV基因组。将在体外重构所得病毒以及扩散缺陷型变体,并使用人源化NOD/SCID/IL 2 Rg-nul小鼠在体外和体内将其生长特征与实验室适应株和其他临床分离株的生长特征进行比较。如果成功,该项目将a)极大地促进直接从序列信息产生CMV的分子克隆,而无需预先组织培养,B)导致迄今为止合成的最大病毒基因组,c)彻底改变疱疹病毒基因组以及其他大DNA病毒基因组的遗传操作。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cloning, Assembly, and Modification of the Primary Human Cytomegalovirus Isolate Toledo by Yeast-Based Transformation-Associated Recombination.
  • DOI:
    10.1128/mspheredirect.00331-17
  • 发表时间:
    2017-09
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Vashee S;Stockwell TB;Alperovich N;Denisova EA;Gibson DG;Cady KC;Miller K;Kannan K;Malouli D;Crawford LB;Voorhies AA;Bruening E;Caposio P;Früh K
  • 通讯作者:
    Früh K
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sanjay Vashee其他文献

Sanjay Vashee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sanjay Vashee', 18)}}的其他基金

Development of FRESH (Fast Rescue Employing Self-Helper virus) - a rapid, generalizable method to rescue infectious virus from noninfectious genomic material
FRESH(使用自助病毒快速救援)的开发 - 一种从非感染性基因组材料中拯救感染性病毒的快速、通用方法
  • 批准号:
    10089402
  • 财政年份:
    2020
  • 资助金额:
    $ 27.31万
  • 项目类别:
Synthetic Genomics to Improve a Phage-Based Diagnostic for Multi-Drug Resistant Bacteria
合成基因组学改进基于噬菌体的多重耐药细菌诊断
  • 批准号:
    9808575
  • 财政年份:
    2019
  • 资助金额:
    $ 27.31万
  • 项目类别:
Combinatory Genomic Assembly to Assess HSV-1 Phenotypes
用于评估 HSV-1 表型的组合基因组组装
  • 批准号:
    8623672
  • 财政年份:
    2013
  • 资助金额:
    $ 27.31万
  • 项目类别:
Combinatory Genomic Assembly to Assess HSV-1 Phenotypes
用于评估 HSV-1 表型的组合基因组组装
  • 批准号:
    8779612
  • 财政年份:
    2013
  • 资助金额:
    $ 27.31万
  • 项目类别:
A Synthetic Human Cytomegalovirus Vaccine Platform
合成人巨细胞病毒疫苗平台
  • 批准号:
    8589435
  • 财政年份:
    2013
  • 资助金额:
    $ 27.31万
  • 项目类别:

相似海外基金

Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 27.31万
  • 项目类别:
    Research Grant
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 27.31万
  • 项目类别:
    Research Grant
Rational Design of live-attenuated vaccines for flaviviruses
黄病毒减毒活疫苗的合理设计
  • 批准号:
    10397675
  • 财政年份:
    2020
  • 资助金额:
    $ 27.31万
  • 项目类别:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
针对脑炎甲病毒的减毒活疫苗的知情方法
  • 批准号:
    10027464
  • 财政年份:
    2020
  • 资助金额:
    $ 27.31万
  • 项目类别:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
针对脑炎甲病毒的减毒活疫苗的知情方法
  • 批准号:
    10405637
  • 财政年份:
    2020
  • 资助金额:
    $ 27.31万
  • 项目类别:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
针对脑炎甲病毒的减毒活疫苗的知情方法
  • 批准号:
    10188419
  • 财政年份:
    2020
  • 资助金额:
    $ 27.31万
  • 项目类别:
Rapid generation and testing of live-attenuated vaccines against SARS-CoV-2
快速生成和测试 SARS-CoV-2 减毒活疫苗
  • 批准号:
    10184147
  • 财政年份:
    2020
  • 资助金额:
    $ 27.31万
  • 项目类别:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
针对脑炎甲病毒的减毒活疫苗的知情方法
  • 批准号:
    10674134
  • 财政年份:
    2020
  • 资助金额:
    $ 27.31万
  • 项目类别:
An Informed Approach to Live Attenuated Vaccines against Encephalitis Alphaviruses
针对脑炎甲病毒的减毒活疫苗的知情方法
  • 批准号:
    10636632
  • 财政年份:
    2020
  • 资助金额:
    $ 27.31万
  • 项目类别:
Live attenuated vaccines to prevent against disease caused by A. pleuropneumoniae
用于预防胸膜肺炎放线杆菌引起的疾病的减毒活疫苗
  • 批准号:
    BB/S000321/1
  • 财政年份:
    2018
  • 资助金额:
    $ 27.31万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了